A Phase 4 interventional study of sugammadex in Brain Tumors, sponsored by Guangzhou General Hospital of Guangzhou Military Command. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-09.
Sponsored by Guangzhou General Hospital of Guangzhou Military Command · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies in Brain Neoplasms with a site in China — 73 open to participants now, 84 under way, 7 of them phase 3. Brain Neoplasms · China.
Among the 180 studies in Brain Neoplasms with a site in China, this one is the 93rd largest by planned enrollment of the 143 interventional ones that give a count, is one of 16 that started in 2020, is one of 3 in phase 4, and was the 91st registered.
2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.
Browse Brain Neoplasms studies →73 of the 180 studies in Brain Neoplasms with a site in China are open now. Recruiting first, the newest first:
Beijing Inno Medicine Co., Ltd. · Sites in China, United States
Ages 18–70
Bristol-Myers Squibb · Sites in China, United States, Belgium and 10 more countries
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–75
Peking University Third Hospital · Sites in China
Ages 18–70
Sun Yat-sen University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 76 · Phase 3 23 · Phase 4 3
First in 1997; this study’s year is marked. 16 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 40 across 1,838 interventional studies indexed under Brain Neoplasms.
Median enrollment 60 across the 143 interventional studies, 358 across the 37 observational. Of the 41 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 180 have an industry lead sponsor. The 10 most frequent:
Guangzhou General Hospital of Guangzhou Military Command is the lead sponsor of 46 studies on the registry; 1 is open to participants now.
Guangzhou General Hospital of Guangzhou Military Command has 1 study filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
17 of the studies in Brain Neoplasms with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07239115Phase 3Beijing Tiantan HospitalLevetiracetam for Seizure Prevention After Brain Tumor Surgery | 2027-01 |
| NCT06457906Phase 3Cancer Institute and Hospital, Chinese Academy of Medical SciencesSRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC | 2027-08-30 |
| NCT07446842Tongji HospitalConstruction of AI Model for Precision Imaging Diagnosis of Cranial Diseases | 2026-12 |
| NCT06231186Ruijin Hospitala Feasibility Study of iHD-SRT for BM | 2026-12 |
| NCT06793332Fudan UniversityBrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC | 2026-12-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 180 studies in Brain Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Effect of sugammadex for reversal of rocuronium-induced neuromuscular block on Perioperative Management of awake Craniotomy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
rocuronium-induced general anesthesia,use of sugammadex antagonism
Drug: sugammadex
general anesthesia without rocuronium
The use of sugammadex
Also known as: Bridion, Org 25969
awake time
The time between asleep and awake
Time frame: 10-30 minutes
Started Sep 2020 (actual). Primary completion is estimated for Feb 2022, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sugammadex
Guangzhou General Hospital of Guangzhou Military Command